New combo therapy shows promise for tough prostate cancer

NCT ID NCT04126070

First seen Jan 23, 2026 · Last updated May 02, 2026 · Updated 11 times

Summary

This study tests a combination of hormone therapy, chemotherapy (docetaxel), and an immunotherapy drug (nivolumab) in 60 men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. Participants must have newly diagnosed, high-volume disease with DNA repair defects or inflamed tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21218, United States

  • University of California, San Diego

    La Jolla, California, 92093, United States

  • University of Wisconsin

    Madison, Wisconsin, 53706, United States

Conditions

Explore the condition pages connected to this study.